What do systematic reviews say?

TACE followed by 3‐DCRT vs chemoembolisation

TACE followed by 3‐DCRT may leads to lower proportion of participants without tumour response (CR+PR) compared with TACE (low certainty).

• Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
  RR 0.49 [0.39, 0.61]
  8 studies · 632 participants
  Low

TACE followed by 3‐DCRT vs chemoembolisation

It is very uncertain whether TACE followed by 3‐DCRT changes proportion of participants without serum AFP normalisation compared with TACE (very low certainty).

• Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 96 participants
  Very low

TACE followed by 3‐DCRT vs chemoembolisation

TACE followed by 3‐DCRT may leads to lower all‐cause mortality: at 3 years compared with TACE (low certainty).

• Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
  RR 0.8 [0.73, 0.88]
  7 studies · 552 participants
  Low

TACE followed by 3‐DCRT vs chemoembolisation

• Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

TACE followed by 3‐DCRT vs chemoembolisation

• Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 66 participants
  Very low

TACE followed by 3‐DCRT vs chemoembolisation

It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: leukopenia compared with TACE (very low certainty).

• Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
  RR 1.12 [0.92, 1.34]
  5 studies · 438 participants
  Very low

TACE followed by 3‐DCRT vs chemoembolisation

It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: serum transaminases elevation compared with TACE (very low certainty).

• Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
  RR 1.67 [0.66, 4.27]
  4 studies · 280 participants
  Very low

TACE followed by 3‐DCRT vs chemoembolisation

It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: total bilirubin elevation compared with TACE (very low certainty).

• Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
  RR 2.69 [1.34, 5.4]
  2 studies · 172 participants
  Very low